IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-hodgkin's lymphoma

Journal of Clinical Immunology

Volumn 31, Issue 6, 2011, Pages 1084-1094

  Feng, Li Li ^a   Gao, Jun Ming ^a   Li, Pei Pei ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

B cell non Hodgkin's lymphoma; Interleukin 9; Mast cells; T regulatory cells; Tumor immunology

Indexed keywords

BETA 2 MICROGLOBULIN; CHYMASE; ESTROGEN RECEPTOR ALPHA; INTERLEUKIN 3; INTERLEUKIN 9; LACTATE DEHYDROGENASE; MAST CELL PROTEASE 5; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 5; SERINE PROTEINASE; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MALE; MAST CELL; METASTASIS; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTIBODIES, BLOCKING; B-LYMPHOCYTES; BONE MARROW; CELLS, CULTURED; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-9; LYMPHOMA, NON-HODGKIN; MAST CELLS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-KIT; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN;

EID: 84857057470     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9584-9     Document Type: Article

References (40)

1. Lippman SM, Spier CM, Miller TP, et al. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol. 1990;3(3):361-7.
2. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol. 2005;23(26):6358-63. (Pubitemid 46218847)
3. Drach J, Seidl S, Kaufmann H. Treatment of mantle cell lymphoma: targeting the microenvironment. Expert Rev Anticancer Ther. 2005;5(3):477-85. (Pubitemid 40903058)
4. Ansell SM, Stenson M, Habermann TM, et al. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol. 2001;19(3):720-6. (Pubitemid 32119086)
5. Lawrence T. Inflammation and cancer: a failure of resolution? Trends Pharmacol Sci. 2007;28(4):162-5. (Pubitemid 46483717)
6. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7(3):211-7. (Pubitemid 40568680)
7. Zou W, Regulatory T. Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol. 2006;6(4):295-307.
8. Ullrich SE, Nghiem DX, Khaskina P. Suppression of an established immune response by UVA-a critical role for mast cells. Photochem Photobiol. 2007;83(5):1095-100. (Pubitemid 47438536)
9. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61 (12):4766-72. (Pubitemid 32691889)
10. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756-61. (Pubitemid 34921025)
11. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-9. (Pubitemid 39273735)
12. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4 +CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173(2):1444-53. (Pubitemid 38924326)
13. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-4. (Pubitemid 35231542)
14. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018-25. (Pubitemid 41291715)
15. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci. 2009;1174:99-106.
16. Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15(20):6446-53.
17. Cao Y, Zhao J, Yang Z et al. CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol. 2010;136(1):21-9.
18. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749-86. (Pubitemid 40563184)
19. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005;6(2):135-42. (Pubitemid 40268194)
20. Galinsky DS, Nechushtan H. Mast cells and cancer-no longer just basic science. Crit Rev Oncol Hematol. 2008;68(2):1 15-30.
21. Taskinen M, Karjalainen-Lindsberg ML, Leppa S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood. 2008;111 (9):4664-7.
22. Huang B, Lei Z, Zhang GM, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008; 112(4):1269-79.
23. Yang Z, Zhang B, Li D et al. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One. 2010;5(1):e8922.
24. Townsend JM, Fallon GP, Matthews JD, et al. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity. 2000;13(4):573-83.
25. Hauber HP, Bergeron C, Hamid Q. IL-9 in allergic inflammation. Int Arch Allergy Immunol. 2004;134(1):79-87. (Pubitemid 38698101)
26. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006;442 (7106):997-1002. (Pubitemid 44330250)
27. Eller K, Wolf D, Huber JM, et al. IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol. 2011;186(1):83-91.
28. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2009;113(15):3546-52.
29. Naito S, von Eschenbach AC, Giavazzi R, et al. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 1986;46(8):4109-15. (Pubitemid 16075915)
30. Feng L, Sun X, Csizmadia E et al. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia. 2010;13(3):206-16.
31. Liu Y, Li N, You L, et al. HSP70 is associated with endothelial activation in placental vascular diseases. Mol Med. 2008;14 (9-10):561-6.
32. Pillai V, Ortega SB, Wang CK, et al. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol. 2007;123(1):18-29. (Pubitemid 46401504)
33. Zhang X, Li M, Lian D, et al. Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol. 2008;127(3):313-21.
34. Gri G, Piconese S, Frossi B, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008;29(5):771-81.
35. Qiao H, Andrade MV, Lisboa FA, et al. FcepsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood. 2006;107(2):610-8. (Pubitemid 43076385)
36. Stassen M, Hultner L, Schmitt E. Classical and alternative pathways of mast cell activation. Crit Rev Immunol. 2002;22 (2):115-40. (Pubitemid 35244754)
37. Wu B, Huang C, Kato-Maeda M, et al. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol. 2008;126(2):202-10.
38. Renauld JC, Kermouni A, Vink A, et al. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. J Leukoc Biol. 1995;57(3):353-60.
39. Elyaman W, Bradshaw EM, Uyttenhove C, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA. 2009;106 (31):12885-90.
40. Hu ZQ, Zhao WH, Shimamura T. Regulation of mast cell development by inflammatory factors. Curr Med Chem. 2007;14 (28):3044-50. (Pubitemid 350226973)